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Edited by Varda RotterAbstract The Escherichia coli verotoxin 1 (VT1) inhibits pro-
tein synthesis, cell proliferation, and damages endothelial cell
in the hemolytic uremic syndrome. VT1 can speciﬁcally bind
and act on endothelial cells as well as on many tumor cells be-
cause these cells express its high aﬃnity receptor, globotriaosyl-
ceramide. This indicates that VT1 may have both antiangiogenic
and antineoplastic activities. We investigated this potential of
VT1 by incubating several colon cancer cell lines with VT1 for
diﬀerent time periods and found that HCT116 cells were espe-
cially sensitive to VT1. A combination of morphological studies,
ﬂow cytometry, DNA laddering and annexin V staining con-
ﬁrmed that VT1 irreversibly arrests these cells in S phase within
24 h and prolonged incubation triggers DNA fragmentation.
Concomitant to the activation of the S phase checkpoint, in-
creased levels of mRNA and proteins of growth arrest and
DNA damage-inducible gene family that include GADD34,
GADD45a, and GADD45b was observed. Interestingly, no sig-
niﬁcant changes in expression of key cell cycle related proteins
such as cdk2, cdk4, p21, p27, and p53 was found during the S
phase arrest and apoptosis. We therefore suggest that GADD
proteins might play an important role in VT1 induced S phase
arrest and programmed cell death in HCT116 cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Verotoxin; Cell cycle; Apoptosis; GADD;
Microarray analysis1. Introduction
Verotoxin 1 (also known as VT1 or Shiga toxin-1 [Stx-1]), a
major cytotoxin produced by VT-producing Escherichia coli
(VTEC) and enterohemorrhagic E. coli plays an important role
in the pathogenesis of hemolytic uremic syndrome (HUS) fol-
lowing an enteric infection [1]. VT1 is known to be cytotoxic
and damages the endothelial cell lining of the glomeruli, and
epithelial cells of the tubule of the kidney, as well as other tis-*Corresponding author. Fax: +81 6 6879 8277.
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sylceramide (Gb3), of the toxin [2]. VT1 action is thought to
involve the induction of a hemorrhagic diarrhea, neurological
damage and apoptosis in some E. coli diseases, including HUS.
Although the exact mechanism of apoptotic cell death is not
yet known, a variety of cell types including Burkitts lym-
phoma, HeLa cells and renal tubular epithelial cells undergo
apoptosis upon exposure to VT1 [3–5].
In the past 20 years, several bacterial toxins have emerged as
powerful therapeutic agents with possible applications in can-
cer, neurological and non-neurological diseases. Currently,
botulinum toxins are used for the treatment of dystonia, spas-
ticity, and muscle overactivity disorders [6]. Anthrax toxin was
shown to inhibit mitogen-activated protein kinase in both nor-
mal melanocyte and melanoma cells, but can only triggers
apoptosis in the latter [7]. Most importantly, the potential
use of VT1 as a clinical agent for malignant meningiomas is
now under investigation [8].
In the work described here, we observed that the human co-
lon cancer cell line HCT116 was especially sensitive to VT1.
These cells provided a means to investigate whether VT1 in-
duced apoptosis in human colon cancer cells in vitro. On the
basis of DNA degradation pattern, ﬂow cytometry, and mor-
phological studies, we have shown for the ﬁrst time to our
knowledge that incubation with VT1 induced a dramatic accu-
mulation of HCT116 cells in S phase followed by programmed
cell death, in a dose and time dependent manner. Moreover, S-
phase arrest was accompanied by increased mRNA and pro-
tein levels of the growth arrest and DNA damage (GADD)
family of genes, including GADD34, GADD45a, and
GADD45b. Taken together, these observations suggest that
E. coli Verotoxin 1 induced a p53/p21-independent cell cycle
arrest and apoptosis in HCT116 colon cancer cells and that
GADD proteins might play an essential role in these events.2. Materials and methods
2.1. Cell lines and cell synchronization
HCT116 cells were grown as monolayer in McCoy medium (Life
Technologies, Rockville, MD) supplemented with 10% fetal bovine
serum, 100 lg/mL streptomycin and 10 U/mL penicillin G. Forblished by Elsevier B.V. All rights reserved.
Fig. 1. Relative sensitivity of human colon cancer cells to VT1. (A)
The graph indicates the percentage of annexin V positive cells (from a
total of 104 cells). All cell lines were treated with VT1 at low dose (5 ng/
ml) for 48 h. Annexin V-FITC staining and cell counting were done as
described in Section 2. Standard deviations are shown with error bars
from mean of at least three diﬀerent experiments. (B) HCT116 cells
were incubated with VT1 (5 ng/ml) for 0, 24, and 48 h. Untreated cells
were lysed by Triton X-100 to ensure maximum release of LDH as a
positive control. LDH release into the culture medium was measured
according to the manufacturers instruction (CytoTox96 kit, Promega).
Results are representative of at least three independent experiments.
(C) Morphological changes in HCT116 cells treated with 5 ng/ml VT1
for 0, 24, 48 h and with HI-VT1 for 48 h (magniﬁcation 400·). Images
were captured by an Olympus 1 · 70 inverted microscope ﬁtted with an
Olympus Camedia C-4040 digital camera.
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treated with 2.5 mM thymidine (Wako Pure Chemical, Osaka, Japan)
for 20 h. Cells were then washed once with PBS and twice with medium
and grown for 6 h. Thymidine (2.5 mM) was added again for an addi-
tional 20 h. Release of the second thymidine block was performed by
washing twice with PBS and three times with medium. Cells were col-
lected after 18 h for ﬂow cytometry analysis.
2.2. VT1 preparation
VT1 was puriﬁed by a modiﬁcation of a method previously de-
scribed involving polymyxin B extraction, and immunoaﬃnity column
chromatography using anti-VT1 rabbit IgG [9]. To detect the presence
of VT1 and/or VT2, VTEC-reversed passive latex agglutination
(VTEC-RPLA) assay (Denka Seiken Co., Tokyo, Japan) was per-
formed according to the manufacturers instructions. Brieﬂy, puriﬁed
VT1 samples were diluted with the supplied diluent. Latex particles
sensitized with rabbit polyclonal anti-VT1 or anti-VT2 IgG antibody
were mixed in appropriate wells. Plates were sealed, incubated at room
temperature, and examined for agglutination after 12–18 h. The posi-
tive and negative control toxins supplied with the kit were employed
in each assay. Heat inactivated (80 C, 15 min) VT1 was not detec-
ted by this kit, and VT2 contamination in the VT1 sample was not
observed.
2.3. DNA fragmentation
Both fragmented DNA and high molecular weight intact genomic
DNA were extracted from 5 · 105 cells using the suicide-Track
DNA ladder isolation kit (Oncogene, Madison, WI). 1.5% Agarose
gel electrophoresis was followed by ethidium bromide staining.
2.4. Annexin V-FITC apoptosis detection assay
The cells were harvested and incubated with VT1 as described
above and washed twice with phosphate-buﬀered saline (PBS).
Staining was carried out using the annexin V-FITC apoptosis detec-
tion kit (BioVision, Mountain view, CA). Brieﬂy, 2 · 105 cells were
resuspended in 1 · binding buﬀer and incubated with annexin
V-FITC and propidium iodide (PI) for 5 min in darkness at room
temperature. Annexin V binding was analyzed by FACScan cytom-
eter (Becton–Dickinson, San Jose, CA) equipped with a FITC signal
detector FL1 (Ex = 488 nm, green) and PI staining by the phycoer-
ythrin emission signal detector FL2 (Ex = 585 nm, red). Percentage
of apoptotic cells was calculated from the total (104 cells) using
FlowJo 4.5.2 software.
2.5. Nucleosome enzyme immunoassay
HCT116 cells were treated with VT1 as described in Fig. 1C. The
presence of nucleosomes in the cytoplasm was determined by ELISA
using mouse monoclonal antibodies directed against DNA and his-
tones according to the manufacturers protocol (Roche, Penzberg, Ger-
many). Enrichment of mono- and oligonucleosomes were calculated
as: enrichment factor = mU of the sample (dying/dead cells)/mU of
the corresponding control (viable cells) where mU = absorbance
[103].
2.6. Cell cycle analysis
For the analysis of DNA content by ﬂow cytometry, cells were trys-
inized, washed in PBS and stained by PI using the CycleTEST and
DNA reagent kits (Becton–Dickinson, San Jose, CA). This method in-
volves dissolving the cell membrane, eliminating nuclear proteins, sta-
bilizing chromatin and staining by PI. Fluorescent light emitted (at
585 nm) from PI-stained nuclei was detected by the FACScans ﬂuores-
cence 2 (FL2) detector. Percentage of cells (from a total of 104 cells) at
diﬀerent phases of the cell cycle was determined using the FlowJo 4.5.2
software and the Watson analysis.
2.7. Immunoblotting
For immunoblotting, cells treated with or without VT1, were
washed with cold PBS and pelleted. The cells were lysed in buﬀer
X + BSA (100 mM Tris–HCl, pH 8.5, 250 mM NaCl, 1% (v/v) NP-
40, 1 mM EDTA, 1 lg/ml aprotinin, 2 mg/ml BSA). Whole cell protein
lysates were solubilized in loading buﬀer, subjected to SDS–PAGE,
and transferred to nitrocellulose followed by incubation with the anti-
bodies as mentioned in the ﬁgure legends.2.8. Cytotoxicity assays
HCT116 cells were grown at 37 C in 5% CO2 in McCoys medium
supplemented with 10% fetal bovine serum. Before incubation with
VT1, cells were washed with phosphate-buﬀered saline (PBS, pH 7.2)
and further incubated with DMEM without phenol red. The release
of lactate dehydrogenase (LDH) into the medium was assayed using
the CytoTox96 Non-radioactive Cytotoxicity Kit (Promega) according
to the manufacturers instructions. At 0, 24 and 48 h post incubation
with VT1, the supernatants were collected, and the release of LDH
was quantiﬁed. LDH release (% cytotoxicity) was calculated using
the following equation: {(OD490 experimental release  OD490 sponta-
neous release)/(OD490 maximum release  OD490 spontaneous re-
lease)} · 100. The spontaneous release is the amount of LDH
released from the cytoplasm of uninfected cells, whereas the maxi-
mum release is the amount released by total lysates of uninfected cells
by Triton X-100.
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HCT116 cells were treated with VT1 (5 ng/ml) for 0, 24, 36 h. Total
RNA was extracted (RNeasy Kit, Qiagen) and double stranded
cDNA was synthesized from 5 lg of total RNA using the Superscript
system (Invitrogen, CA) primed with a T7-(dT)-24 primer. To pre-
pare biotin labeled cRNA from this cDNA, an in vitro transcription
reaction was performed in the presence of T7 RNA polymerase and
biotinylated ribonucleotides (Enzo Diagnostics, NY). The cRNA
product was puriﬁed (RNeasy Kit, Qiagen), fragmented, and hybrid-
ized to a human genome focus array chip, as per the manufacturers
instruction (Aﬀymetrix, CA). The chips were washed and scanned
with a GeneArray scanner (Aﬀymetrix). The color intensity of gene
expression was generated with the Gene Spring6.0 software (Silicon
Genetics).3. Results
3.1. Relative sensitivity of colon cancer cell lines to VT1
Host sensitivity to VT1 varies according to the speciﬁc cellu-
lar expression of its Gb3 receptor [10]. VT1 was also shown to
reduce cell viability in a dose and time-dependent manner. To
study the relative sensitivity of colon cancer cells, ﬁve cell lines
including four colon cancer cell lines were monitored for 48 h
after exposure to a low concentration (5 ng/ml) of VT1. Cellu-
lar shrinkage and cell rounding, two typical morphologic
changes occur in apoptosis, started appearing in HCT116 cells
from 24 h of VT1 treatment and a signiﬁcant increase in these
characteristics were observed after 48 h of incubation. Incubat-
ing the same cells with heat inactivated (HI) VT1 (80 C for
15 min) produced no signiﬁcant morphological changes
(Fig. 1A), also excluding the possibility of LPS contamination
in the VT1 preparation.
To understand if this cytotoxic eﬀect was, at least in part,
due to apoptosis, all cell lines were stained with annexin V-
FITC. Fluorescence analysis showed that 40% of HCT116 cells
were apoptotic compared to only 5–18% in other colon cancerFig. 2. DNA fragmentation and annexin V binding analysis showing inductio
from HCT116 and T84 cells either untreated or treated with VT1 (5 ng/ml)
staining. (B) HCT116 cells were incubated with VT1 as described above. Per
binding with by ﬂow cytometry and using the FlowJo 4.5.2 software. Viable c
apoptotic cells show annexin V staining, but exclude PI (lower right quadr
positive (upper right quadrant).cell lines (Fig. 1B). Therefore, we used the HCT116 cell line in
our further studies aimed to understand the mechanism of VT1
mediated programmed cell death.
LDH, a stable cytosolic enzyme, was shown to be released
upon cell lysis during necrosis and at later stages of apoptosis
[11]. Consistent with the annexin V staining result, LDH activ-
ity in HCT116 cells was increased up to 45% only after 48 h of
VT1 incubation (Fig. 1C).
3.2. DNA fragmentation in HCT116 cells exposed to VT1
Based on LDH activity and phase contrast microscopy fur-
ther studies were extended by DNA fragmentation and annex-
in V staining. Total DNA (genomic and fragmented) was
prepared from VT1-exposed HCT116 cells after 0, 24, 48 h,
and from cells treated with HI VT1 for 48 h. Electrophoretic
patterns indicating DNA fragmentation were seen in cells trea-
ted with VT1 for 48 h, but not in 0 h cells. The DNA also
remained intact in cells after 24 h of incubation with VT1
and 48 h of incubation with HI-VT1 (Fig. 2A). T84, another
colon cancer cell line, was resistant to VT1-induced apoptosis,
since no apoptotic ladders were observed using the condition
described above (Fig. 2B). The fragmented DNA formed a lad-
der of starting with 190 bp and up, suggesting that cleavage oc-
curred at the internucleosomal regions, characteristic to cells
commit programmed cell death.
To support and extend the DNA fragmentation experi-
ments, we performed double staining using annexin V-FITC
and PI followed by ﬂow cytometry. Fig. 2C shows that in cells
treated with VT1 for 0, 24, and 48 h, 18.7% and 33% cells were
positive (right-bottom quadrant) for phosphatidyl-serine, rep-
resenting early stages of apoptosis. No signiﬁcant changes were
observed either in control and or in HI-VT1-treated cells indi-
cating that the percentage of apoptotic cells in the total cell
population was the same when diﬀerent methods to detect
apoptosis were applied.n of apoptosis. (A) Agarose gel (1.5%) electrophoresis of DNA isolated
and HI-VT1 (5 ng/ml) for 24, and 48 h followed by ethidium bromide
cent apoptotic cells was detected by analyzing annexin V-FITC and PI
ells do not display annexin V or PI staining (lower left quadrant), early
ant), and necrotic, or late apoptotic cells are both annexin V and PI
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VT1 binds to the cellular receptor Gb3 and is internalized
into the cytoplasm. The entire internalization process requires
more than an hour of incubation with the cells [12]. To test
whether the ﬁndings described above resulted from speciﬁc
functions exerted by VT1, HCT116 cells were incubated with
VT1 for 0, 0.5 and 2 h. Cells were then washed extensively to
remove unbound toxin and incubated for another 48, 47.5
and 46 h, respectively, in fresh medium without VT1. DNA
fragmentation was occurred in cells (Fig. 3A) those were ex-
posed with VT1 for 2 h, indicating that the removal of extra-
cellular VT1 were unable to halt the signaling events
initiated in these cells in the ﬁrst 2 h. A progressive increase
in the percentage of rounded/shrunken cells was observed
and eventually approximately 70–80% of the cell population
detached from the culture dish 72 h after washing VT1 (data
not shown). Therefore, once VT1 could enter the host cell
cytoplasm, its eﬀects are irreversible.
The cytoplasm of the apoptotic cells is enriched in mono and
oligonucleosomes owing to the DNA degradation that occurs
prior to the breakdown of the plasma membrane. We observed
such response in VT1-treated cells by a quantitative sandwich-
enzyme-immunoassay that can speciﬁcally determinate the
mono and oligonucleosomes in the cytoplasmic fraction of cell
lysates, by using mouse monoclonal antibodies directed
against DNA and histones. The enrichment factor (see the cal-
culation in Section 2) of nucleosomes in the cytoplasm ofFig. 3. Enrichment of nucleosomes in the cytoplasm of cells treated
with VT1. (A) DNA fragmentation analysis was done as described in
Fig. 2A. 46-h PW (46 h after washing) indicates that HCT116 cells
were incubated with VT1 for 2 h and then washed with PBS and fresh
mediaum to remove unbound toxins, followed by 46 h incubation in
fresh medium. (B) HCT116 cells were treated as described in Fig. 2A.
After cell lysis and centrifugation, the cytoplasmic fractions were
diluted 1:10 with incubation buﬀer (ELISA kit; Roche, Penzberg,
Germany) and tested for nucleosome presence using mouse monoclo-
nal antibodies speciﬁc for DNA and histones.HCT116 cells treated with VT1 for 48 h increased 4-fold com-
pared to control cells and HI-VT1 treated cells (Fig. 3B).
3.4. VT1 activates the S phase checkpoint
It has been suggested that activation of cell cycle checkpoints
is often involved in the initiation of apoptosis [13]. To examine
the eﬀect of VT1 on cell cycle progression, we analyzed the
DNA content of HCT116 cells treated with VT1 and HI-
VT1 by ﬂow cytometry. After 18 and 24 h of treatment with
VT1, there was a gradual increase in the S phase population
(Fig. 4A), from 15% at 0 h to 28% at 18 h and 40% at 24 h,
accompanied by a sharp decline in the number of cells in G1
phase (from 73% at 0 h to 34% at 24 h). Importantly, in cells
treated with VT1 for 48 h a sub-G1 (>G1) peak appeared indi-
cating apoptosis (48 h in Fig. 4B). Cells treated with HI-VT1
exhibited normal cell cycle distribution (Fig. 4B). This suggests
that a small number of cells escaped from the S phase arrest
and undergo apoptosis. When comparing the characteristics
of S phase arrest caused by thymidine and VT1, ﬂow cytome-
try analysis showed that 18 h after the release from the thymi-
dine block, cells previously accumulating in S phase progressed
normally through the cell cycle, while a high proportion of
VT1 treated cells still remained arrested in S phase (Fig. 4C).
Based on the combination of cell cycle experiments and
DNA fragmentation analysis, we conclude that VT1 exposure
exerts leave a permanent, irreversible eﬀect on these cells.
3.5. VT1 treatment up-regulates GADD family proteins and
mRNA
To further investigate the possible mechanism(s) of this S
phase arrest and apoptosis in cells treated with VT1, we em-
ployed cDNA microarray analysis to analyze global changes
in gene expression. Due to the large number of genes modu-
lated during 24 and 36 h after VT1 exposure, the data were ﬁl-
tered and 4-fold changes (compare to uninduced) and greater
at both 24 and 36 h of VT1 incubation are shown. Among such
changes, the induced genes contain those that were previously
shown to be associated with the cell cycle, DNA damage and
apoptosis (Fig. 5A). To determine whether the changes in
RNA levels reﬂect a change in the protein produced, we ana-
lyzed the levels of various cell cycle/apoptosis regulating pro-
teins by western blotting (Fig. 5B). We found that the level
of three GADD family genes GADD45a, GADD45b, and
GADD34, the activating transcription factor (ATF3) and
one cell cycle related phosphatase, CdkN3, gradually increased
in cells treated with VT1 for 24 and 36 h (Fig. 5A). Interest-
ingly, the protein levels of key cell cycle regulators such as
cdk2, cdk4, p21, p27, and p53 did not changed signiﬁcantly
as the result of prolonged VT1 treatment. Consistent with
mRNA induction, western blot analysis also revealed a VT1-
mediated upregulation of GADD45a, GADD45b, and
GADD34. The expression level of housekeeping genes
(GAPDH and b-actin) and protein did not change in micro-
array and western blot during this period of HCT116 cell incu-
bation with VT1 (Fig. 5A and B).4. Discussion
E. coli verotoxin 1 (VT1) is a potent cytotoxin involved
in the pathogenesis of hemorrhagic colitis and is known to
cause microvasculopathies of the colon. VT1 causes damage
Fig. 4. Cell cycle progression of HCT116 cells after treatment with VT1. (A,B) Cells were treated as described in Fig. 2C, then ﬁxed, stained with PI,
and examined for DNA content by ﬂow cytometer. The peaks represent the cells in G0–G1, S, and G2-M. Subdiploid apoptotic DNA is marked
>G1. A total of 104 nuclei, per sample, analyzed. (C) Cells were grown in the presence of thymidine (see Section 2) and VT1. To release from
thymidine and VT1 toxin, cells were washed extensively with PBS and medium and incubated for an additional 18 h and cell cycle analysis was
performed as described above.
Fig. 5. Eﬀect of VT1 treatment on gene transcription and protein expression in HCT116 cells. (A) Cells were untreated, or treated with VT1 (5 ng/ml)
for 24 and 36 h. Biotin labeled cRNA prepared from cells was hybridized to spotted human genome microarray chips. High quality spots (signal
strength of three times over background) were organized into gene expression clusters. Genes those changed more than 2-fold were given a color
image based on intensity of gene expression. (B) Cells were either untreated, or treated with VT1 (5 ng/ml) for 24 and 48 h. Whole cell protein extracts
were solubilized in loading buﬀer, boiled for 3 min at 100 C, subjected to 10% SDS–PAGE, and transferred to nitrocellulose membrane before
immunoblotting with antibodies as indicated in the ﬁgure.
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variety of cell types that express its speciﬁc Gb3 receptor
[14]. The exact mechanism(s) by which VT1 trigger the apop-
totic signal are not well deﬁned [4,5]. Interestingly, expression
of the VT1 receptor Gb3 on human cancer cell lines including
renal carcinoma, melanoma, prostate cancer, and testicular tu-mors suggest that further studies on the mechanism of VT1-
mediated signaling pathway(s) might be beneﬁcial if VT1 has
an antineoplastic potential. Recent studies have shown that
in mice harboring tumor xenografts originating from Gb3-po-
sitive human renal, prostate cancer and malignant meningio-
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Fig. 6. A proposed pathway for VT1 action in HCT116 cells. A
hypothetical model describes the involvement of ATF3 and GADD
family members in mediating apoptosis in colon cancer HCT116 cells
by VT1.
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upon recognition of the Gb3 glycolipid receptor of tumor cells
and tumor neovasculature, the rationale for using VT1 in anti-
tumor clinical application will only be possible if its functional
mechanism is unraveled. Aiming to this, we studied the mech-
anism of VT1 action in a VT1-sensitive human colon cancer
cell line HCT116. DNA fragmentation, annexin V staining
and nucleosomal (DNA plus histones) assays showed that
VT1 kills these cells through an apoptotic pathway. Flow cyto-
metric analysis showed an increase in the subG0/G1 cell pop-
ulation, a hallmark of apoptosis, when these cells were
incubated with VT1 for 48 h. Unlike the reversible S phase
blocker thymidine, releasing cells from the VT1 block after
6 h of incubation by extensive washing made no diﬀerence in
the ongoing signaling events that ultimately led to S phase ar-
rest and eventually to apoptosis (Figs. 3 and 4). Within this
time period, the processes of Gb3 recognition by VT1 and
the subsequent internalization of VT1 by endocytosis were
completed and the signaling events initiated in these cells by
VT1 are irresistible.
Apoptosis is regarded as one of the important defense mech-
anisms in the event of cell and DNA damage, because it trig-
gers a series of controlled signaling mechanisms including
cell cycle arrest and DNA repair to protect the genome from
defective DNA synthesis [16]. One of the principal causes of
S phase arrest is DNA damage [17]. The S phase arrest induced
by the VT1 toxin is most likely the consequence of irreversible
DNA damage. It is possible that part of such cells damaged be-
yond the capacity to repair their DNA, progress to pro-
grammed cell death, since after 48 h a sub-G1 population
became evident.
We further conﬁrmed that the GADD family of genes was
upregulated both at mRNA and protein levels by VT1 and
was coupled with the induction of S phase arrest. Growth-ar-
rest and DNA damage-inducible genes were found to be stress
response genes often increased when cells are subjected to a
stressful environment such as chemical carcinogens, UV radia-
tion, hypoxia, or apoptosis inducing agents such as stauro-
sporine and anti-Fas antibodies [18–20]. The GADD34
protein speciﬁcally binds to a wide range of cellular proteins
involved in growth arrest, apoptosis and DNA repair [21,22].
ATF3, another stress response gene, plays a critical role in
enhancing caspase activation during etoposide-induced apop-
tosis without aﬀecting the expression of Bcl-2, or Bax [23]. In
addition, ATF3 is required for increased expression of
GADD34 and the apoptosis inducing protein CHOP (also
known as GADD153) [24,25]. It was shown that NF-jB/IjB
signaling is a critical regulator of cell survival. Recent work
demonstrated that induction of apoptosis by NF-jB inhibitor
resulted from induction of GADD45a and c expression in
prostate cancer cells, and a c-Myc dependent downregulation
of GADD45a/c protein expression was associated with NF-
jB-mediated escape from programmed cell death in cancer
cells [26]. Although the exact biological signiﬁcance of GADD
upregulaion in VT1 treated cells is not known, the eﬀect of
VT1 on GADD expression might contribute to the capacity
of VT1 to induce S phase arrest and apoptosis. p53 was also
analyzed to determine if it is a regulator of the VT1 eﬀect on
GADD expression, since this transcription factor is activated
under oxidative stress, and DNA damage [27]. Both the
RNA and protein expression studies of p53, the p53-related
cell cycle inhibitors p21, p27 and kinase Cdk4 imply thatGADD expression occurred independently of these factors.
Thus in HCT116 cells, VT1 and the bile salt deoxycholate
(DOC) induce a similar response by initiating common signal-
ing pathways. When both HCT116 (containing wild type p53)
and HCT-15 (containing mutant p53) colon cancer cells were
exposed to DOC, DNA damage and apoptosis were observed
with increased GADD expression, regardless of their p53 sta-
tus [28]. Taken together, our data suggest that p53, p21, p27
and Cdk4 might not be a necessary prerequisite for VT1 in-
duced cell cycle arrest and apoptosis in this cell line. On the ba-
sis of these observations, we proposed a hypothetical model
(Fig. 6) indicating the signaling pathways involving cell cycle
arrest, DNA damage, ATF3, GADDs and apoptosis.
Bacterial toxins are considered as potential therapeutic
agents for various diseases. When athymic nude mice carrying
human melanoma xenograft were treated with the anthrax
lethal factor (LeTx), complete tumor regression without appar-
ent side eﬀects were observed [7]. VT1 has also proved highly
eﬀective in a xenograft cancer model [12]. The precise mecha-
nism by which VT1 blocks S phase progression of the colon
cancer cell line HCT116 remains incompletely deﬁned. How-
ever, for the ﬁrst time to our knowledge, this ﬁnding would
add the VT1-mediated upregulation of the GADD family of
genes to the growing list of apoptotic pathways initiated by
this E. coli toxin in various cell lines and tumor xenografts.
Further studies along these lines are warranted before the
use of VT1 as a potential therapeutic agent in experimental
medicine.
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